Ben Taylor

Ben is an associate in Goodwin’s Technology and Life Sciences group specializing in venture capital financings and M&A transactions. Ben advises clients on a broad range of corporate matters, with a particular focus on emerging growth companies and venture capital investors. Ben advises clients through every stage of the corporate life cycle.

• Scalpel AI on its £3.8 million funding round led by Mercia Ventures. Scalpel AI is an AI platform for the surgical supply chain, enhancing productivity and reducing errors in surgical workflows by automatically identifying and classifying surgical inventory without tags
• Montage Ventures on its lead investment in a $6.5 million seed round for CardiaTec. Founded in 2021, CardiaTec is leveraging artificial intelligence and multi-omics data to revolutionize drug target discovery for cardiovascular diseases
• Ophelos on its sale to Intrum, a Swedish-headquartered company listed on the Nasdaq Stockholm stock exchange and a market leading European credit management company with operations in more than 20 countries
• Fractile on its $15 million seed financing, led by Kindred Capital, the NATO Innovation Fund, and Oxford Sciences Enterprises. Founded in 2022, Fractile is a British startup that develops chips for AI applications
• Sound Bioventures on its investment in the recent £19 million financing round of Theolytics. Theolytics is developing oncolytic viral therapy for the treatment of ovarian cancer

Prior to joining Goodwin, Ben was head of the Corporate & Securities team at Hopin, Europe's then fastest growing start up. During his time at Hopin, Ben guided the business through $950 million of financings and acquired five technology companies.

Prior to joining Hopin, Ben spent five years in the London office of Cooley, another leading law firm in the venture and M&A space where he focused on tech M&A, private equity, and venture financings.